Review anchor
Glutamate receptor ionotropic, NMDA 2B
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Glutamate receptor ionotropic, NMDA 2B
CHEMBL1904
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Glutamate receptor ionotropic, NMDA 2B as ChEMBL target CHEMBL1904, mapped to UniProt Q13224. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL1904
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q13224
Glutamate receptor ionotropic, NMDA 2B
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Glutamate receptor ionotropic, NMDA 2B matters
Glutamate receptor ionotropic, NMDA 2B is reviewed as Glutamate receptor ionotropic, NMDA 2B (UniProt Q13224); the current evidence base includes 0 approved drugs, 2104 compounds, and 167 assays, with lead potency reaching pChEMBL 9.2.
Protein context
Glutamate receptor ionotropic, NMDA 2B
Glutamate receptor ionotropic, NMDA 2B Sequence length is 1484 aa.
Review this target as Glutamate receptor ionotropic, NMDA 2B, mapped to UniProt Q13224. Sequence length is 1484 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q13224
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 0 approved drugs, 2104 compounds, and 167 assays for this target. The dominant activity type is IC50. CHEMBL161180 is the current potency anchor at pChEMBL 9.2.
Use CHEMBL161180 as the tractability anchor when discussing potency (pChEMBL 9.2).
Activity source · ChEMBL 36 via Core Engine
pChEMBL 9.2
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Glutamate receptor ionotropic, NMDA 2B matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q13224, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
2104
Total Compounds
167
Total Assays
0
Approved Drugs
IC50: 2017.0, KI: 242.0, EC50: 48.0, KD: 3.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL161180
|
9.2 | Ki | — |
|
|
No preferred name
CHEMBL158737
|
9.2 | Ki | — |
|
|
No preferred name
CHEMBL158737
|
9.0 | Kd | — |
|
|
No preferred name
CHEMBL159744
|
8.9 | Ki | — |
|
|
No preferred name
CHEMBL219060
|
8.8 | EC50 | — |
Source Header